TY  - JOUR
AU  - Cabo, Mariona
AU  - Offringa, Rienk
AU  - Zitvogel, Laurence
AU  - Kroemer, Guido
AU  - Muntasell, Aura
AU  - Galluzzi, Lorenzo
TI  - Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.
JO  - OncoImmunology
VL  - 6
IS  - 12
SN  - 2162-4011
CY  - Abingdon
PB  - Taylor & Franics
M1  - DKFZ-2021-03066
SP  - e1371896 -
PY  - 2017
N1  - POF Topic: 317
AB  - The goal of cancer immunotherapy is to establish new or boost pre-existing anticancer immune responses that eradicate malignant cells while generating immunological memory to prevent disease relapse. Over the past few years, immunomodulatory monoclonal antibodies (mAbs) that block co-inhibitory receptors on immune effectors cells - such as cytotoxic T lymphocyte-associated protein 4 (CTLA4), programmed cell death 1 (PDCD1, best known as PD-1) - or their ligands - such as CD274 (best known as PD-L1) - have proven very successful in this sense. As a consequence, many of such immune checkpoint blockers (ICBs) have already entered the clinical practice for various oncological indications. Considerable attention is currently being attracted by a second group of immunomodulatory mAbs, which are conceived to activate co-stimulatory receptors on immune effector cells. Here, we discuss the mechanisms of action of these immunostimulatory mAbs and summarize recent progress in their preclinical and clinical development.
KW  - CD137 (Other)
KW  - CD40 (Other)
KW  - GITR (Other)
KW  - ICOS (Other)
KW  - OX40 (Other)
KW  - PD-1 (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:29209572
C2  - pmc:PMC5706611
DO  - DOI:10.1080/2162402X.2017.1371896
UR  - https://inrepo02.dkfz.de/record/178057
ER  -